-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4356 Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events

Program: Oral and Poster Abstracts
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
MPN, elderly, Chronic Myeloid Malignancies, Diseases, Adverse Events, Myeloid Malignancies, Study Population, Human
Monday, December 12, 2022, 6:00 PM-8:00 PM

Roberto Latagliata, MD1*, Alessandro Andriani2*, Massimo Breccia, MD3*, Ida Carmosino, MD4*, Federico Vozella, MD5*, Atelda Romano, MD6*, Annalisa Biagi, MD7*, Luca Maurillo, MD8*, Malgorzata Monika Trawinska, MD9*, Katia Paciaroni, MD10*, Michelina Santopietro, MD11*, Sabrina Leonetti Crescenzi, MD12*, Ada D'Addosio, MD13*, Caterina Tatarelli, MD, PhD14*, Elisabetta Abruzzese, MD15, Ambra Di Veroli, MD1*, Elena Rossi, MD, PhD16*, Valerio De Stefano, MD16* and Marco Montanaro, MD17*

1Hematology, Belcolle Hospital, Viterbo, Italy
2Latial Group for the Study of Myeloproliferative Neoplasms, Rome, Italy
3Division of Hematology, Department of Translational and Precision Medicine, Azienda Policlinico Umberto I, Sapienza University, Rome, Italy
4Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
5Hematology and Stem cell transplantation, Campus Biomedico University, Rome, Italy
6Hematology, Istituto Nazionale Tumori Regina Elena - IFO, Rome, Italy
7Hematology, Santa Maria Goretti Hospital – Polo Pontino “Sapienza” University, Latina, Italy
8Department of Onco-Hematology, Policlinico Tor Vergata, Rome, Rome, Italy
9Hematology S. Eugenio Hospital, ASL RM2, Rome, Italy
10UOSD Hematology, ASL RM1, Rome, Italy
11U.O. di Ematologia e Trapianti di cellule Staminali. A.O.S. S. Camillo-Forlanini, Rome, Italy
12S.C. Ematologia, Azienda Ospedaliera S Giovanni Addolorata, Roma, Italy
13Hematology, Villa San Pietro Hospital, Rome, Italy
14Hematology, Sant'Andrea Hospital - University Sapienza of Rome, Roma, ITA
15Department of Hematology S. Eugenio Hospital, Rome, Italy
16Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A Gemelli, IRCCS, Rome, Italy
17Hematology, Belcolle Hospital, Viterbo, ITA

Background Thrombotic events are the major complications in patients (pts) with Essential Thrombocythemia (ET). Occurrence of thrombotic events before ET diagnosis is a worldwide recognised risk factor for thrombosis in the follow-up of ET pts: age > 60 years is another risk factor, but its role in pts without previous thrombotic events needs to be further defined with the addition of other potential risk factors.

Methods To assess prognostic role of different putative risk factors for thrombosis in a wide cohort of elderly pts, we revised clinical features, follow-up and thrombotic events in 956 ET pts aged > 60 years diagnosed from 1/2000 to 12/2016 and enrolled in the retrospective and prospective registries of Latial Group for the Study of Myeloproliferative Neoplasms.

Results On the whole, 191/956 pts (20.0%) (Group A) had a story of previous thrombotic events before ET diagnosis (arterial in 139 pts and venous in 52 pts): of them, 27 had at least one thrombotic event in the ET follow-up, with a 3- and 5-year cumulative incidence of thrombosis of 10.7% (95%CI 5.8 – 15.6) and 18.8% (95%CI 11.8 – 25.8), respectively. Among the remaining 765 pts (80.0%) without any thrombotic event before ET diagnosis (Group B), 59 reported at least one thrombotic event, with a 3- and a 5-year cumulative incidence of 2.7% (95%CI 1.6 – 3.8) and 5.7% (95%CI 3.8 – 7.6), respectively. The main clinical features at ET diagnosis of the entire cohort and according to the occurrence of previous thrombosis before ET diagnosis were reported in the Table: pts in the Group A had a higher WBC median value and a higher rate of dyslipidaemia compared to pts in the Group B. The following putative risk factors for thrombosis were evaluated in the Group B pts: gender, age>75 years, WBC, PLTs, Hb, spleen enlargement, JAK-2-V617F mutation and allele burden, hypertension, diabetes, smoke attitude, dyslipidaemia). Only the presence of hypertension showed a prognostic significance (3- and 5-year cumulative incidence of thrombosis of 4.7% and 8.2%, respectively, vs 0.6% and 3.1% in pts without hypertension, p=0.016).

Conclusions While previous thromboses before ET diagnosis and age > 60 years are generally regarded in a similar way as thrombotic risk factors, the risk related to age > 60 years per se seems lower: in addition, in ET pts aged > 60 years without previous thrombosis, only hypertension seems to have a predictive role and needs to be carefully controlled.

Disclosures: Latagliata: BMS: Honoraria; Novartis: Honoraria. Breccia: Novartis, Incyte, Pfizer, BMS, Abbvie: Honoraria. Abruzzese: BMS, Incyte, Novartis, Pfizer: Consultancy. Rossi: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. De Stefano: AbbVie: Honoraria; Amgen: Honoraria, Speakers Bureau; Bristol Myers Squibb/Celgene: Honoraria, Speakers Bureau; GlaxoSmithKline: Honoraria, Speakers Bureau; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH